Press Releases
August 2, 2010
Diffusion Pharmaceuticals Announces Issuance of New U.S. Patent
CHARLOTTESVILLE, VA –August 2, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,759,506 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes drug formulation and use claims relating to Diffusion’s entire family of first-in-class new chemical entities. [...]
March 22, 2010
Diffusion Pharmaceuticals LLC Wins Inaugural Perfect Pitch Competition –Biotech Investment Challenge –at BioNetwork East Conference in Miami, FL
Charlottesville, VA — March 22, 2010 —Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced its selection as the winner of the Perfect Pitch Competition – Biotech Investment Challenge. The winner was announced during a special awards ceremony attended by over 150 delegates and [...]
February 23, 2010
Diffusion Pharmaceuticals LLC Announces Publication of Three Studies Testing Trans Sodium Crocetinate (TSC); Statistically significant results seen in animal models of primary brain cancer, cerebral ischemia and stroke
Charlottesville, VA –February 23, 2010 – Diffusion Pharmaceuticals LLC today announced that three separate preclinical studies testing its lead drug candidate trans sodium crocetinate, (TSC), have been published in peer-reviewed journals during the last six months. These studies demonstrate that TSC improves tissue oxygenation in hypoxic brain tumor tissue, exerts a neuroprotective effect against ischemic [...]
January 29, 2010
Diffusion Pharmaceuticals LLC Closes on $5.9 Million Financing
CHARLOTTESVILLE, VA – January 29, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million. The [...]
January 4, 2010
Diffusion Pharmaceuticals LLC Announces Addition of Dr. David R. Jones as Chief Medical Officer, and Dr. Guy M. Chisolm Joins its Scientific Advisory Board
CHARLOTTESVILLE, VA – Wednesday, January 6, 2010 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that David R. Jones, M.D., has joined its staff as Chief Medical Officer and member of its Scientific Advisory Board (SAB). In addition, Guy M. Chisolm, Ph.D., [...]
February 25, 2009
Diffusion Pharmaceuticals Featured in NPR Story on New Stroke Treatment
Scientists in Charlottesville are studying what could be a whole new approach to treating stroke—the nation’s leading cause of disability and the third leading cause of death. WVTF’s Sandy Hausman reports on the research. Listen Dr. Lee is chair of the Department of Neuroscience at the University of Virginia School of Medicine, and will present [...]
February 6, 2009
Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
CHARLOTTESVILLE, VA – February 6, 2009 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs that enhance oxygen diffusion, today announced the completion of a $2.9 million private placement. The proceeds will support the company’s overall growth and clinical programs for its lead drug compound, trans sodium crocetinate (TSC). In addition, David [...]
